Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

Acta Neuropathol. 2004 Jul;108(1):49-56. doi: 10.1007/s00401-004-0861-z. Epub 2004 Apr 28.

Abstract

We carried out a population-based study on low-grade diffuse gliomas in the Canton of Zurich, Switzerland (population 1.16 million). From 1980 to 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 122 (12.4%) were low-grade (WHO grade II). The incidence rates adjusted to the World Standard Population, per million population per year, were 2.28 for low-grade diffuse astrocytomas, 0.89 for oligoastrocytomas, and 2.45 for oligodendrogliomas. The survival rate (mean follow-up 7.5+/-4.8 years) was highest for patients with oligodendroglioma (78% at 5 years, 51% at 10 years), followed by those with oligoastrocytoma (70% at 5 years, 49% at 10 years) and fibrillary astrocytoma (65% at 5 years, 31% at 10 years). Survival of patients with gemistocytic astrocytoma was poor, with survival rates of 16% at 5 years and 0% at 10 years. Younger patients (<50 years) survived significantly longer than older patients (>50 years; P=0.013). DNA sequencing, performed in 84% of cases, revealed that TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but were infrequent (13%) in oligodendrogliomas. The presence of TP53 mutations was associated with shorter survival of patients with low-grade diffuse gliomas (log-rank test; P=0.047), but when each histological type was analyzed separately, an association was observed only for oligoastrocytoma ( P=0.05). Loss on 1p and 19q were assessed by quantitative microsatellite analysis in 67% of cases. These alterations were frequent in oligodendrogliomas (1p, 57%; 19q, 69%), less common in oligoastrocytomas (1p, 27%; 19q, 45%), rare in fibrillary astrocytomas (1p, 7%; 19q, 7%), and absent in gemistocytic astrocytomas. None of these alterations were predictive of survival. These results establish the frequency of key genetic alterations in low-grade diffuse gliomas at a population-based level. Multivariate Cox's regression analysis indicates that only age and histological type, but not genetic alterations, are significant predictive factors.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Astrocytoma* / epidemiology
  • Astrocytoma* / genetics
  • Astrocytoma* / mortality
  • Astrocytoma* / surgery
  • Chromosomes, Human, Pair 1
  • Chromosomes, Human, Pair 19
  • DNA Mutational Analysis / methods
  • Exons / genetics
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Loss of Heterozygosity / physiology
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Mutation
  • Neurosurgical Procedures / methods
  • Oligodendroglioma* / epidemiology
  • Oligodendroglioma* / genetics
  • Oligodendroglioma* / mortality
  • Oligodendroglioma* / surgery
  • Retrospective Studies
  • Sex Factors
  • Survival Rate
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Tumor Suppressor Protein p53